SAN DIEGO, June 20, 2016 /PRNewswire/ -- ResMed (NYSE:RMD)
today issued the following statement related to Brightree's
announcement of its new executive team, from president of
healthcare informatics Raj Sodhi:
"Matt Mellott and Bobby Ghoshal join an exceptional senior
leadership team with a commitment to customer-centered innovation
and a culture of excellence. They will continue moving Brightree
forward, expanding on the company's leadership in business
management and clinical software applications for the post-acute
care industry."
"Brightree wouldn't be the company it is today without the
leadership of Dave Cormack, whose
tenure as president and CEO began in 2005. We're pleased Dave has
agreed to stay on in an advisory role to ensure a smooth
transition."
"ResMed and Brightree will continue to shape the frontier of
digital health. Their innovations in software, informatics and
devices will continue to improve patients' quality of life, slow
the progression of chronic diseases and lower overall healthcare
system costs while enabling HMEs and other post-acute care
providers to better manage their businesses and optimize patient
care."
About ResMed
ResMed (NYSE:RMD) changes lives with
award-winning medical devices and cutting-edge cloud-based software
applications that better diagnose, treat and manage sleep apnea,
chronic obstructive pulmonary disease (COPD) and other chronic
diseases. ResMed is a global leader in connected care, with more
than 1 million patients remotely monitored every day. Our
5,000-strong team is committed to creating the world's best
tech-driven medical device company – improving quality of life,
reducing the impact of chronic disease, and saving healthcare costs
in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
For
media:
|
For
investors:
|
Alison
Graves
|
Agnes Lee
|
Director, Corporate
Communications
|
Senior Director,
Investor Relations
|
O:
858-836-6789
|
O:
858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/resmed-statement-on-brightree-executive-appointments-300286850.html
SOURCE ResMed Inc.